Novel asthma therapies: A review

Current Drug Therapy

Volumn 7, Issue 1, 2012, Pages 30-35

  Chopra, Preeti ^a   Randhawa, Inderpal ^a,b   Chin, Terry ^b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti Inflammatory Medications; Asthma; Immunotherapy; Inhaled Bronchodilators; Inhaled Corticosteroids; Monoclonal Antibody

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BENRALIZUMAB; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CARMOTEROL; CICLESONIDE; ENOKIZUMAB; ETANERCEPT; FLUTICASONE; FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTIFORM; FORMOTEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUMARATE; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; INDACATEROL; INTERLEUKIN 5 ANTIBODY; MEPOLIZUMAB; MONOCLONAL ANTIBODY; OGLEMILAST; PLACEBO; RESLIZUMAB; ROFLUMILAST; TOFIMILAST; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ASTHMA; BRONCHODILATATION; CANDIDIASIS; CHILL; CROHN DISEASE; DISEASE EXACERBATION; ERYTHEMA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HOSPITALIZATION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84860516160     PISSN: 15748855     EISSN: 10657630     Source Type: Journal    
DOI: 10.2174/157488512800389182     Document Type: Review

References (52)

1. th ed. WB Saunders Company 2001.
2. National Asthma Guidelines Updated. National Institute of Health. http://www.nih.gov/news/pr/aug2007/nhbli-29.htm. August 27, 2007.
3. th ed. WB Saunders Company 2001.
4. th ed. McGraw-Hill Professional 2005.
5. Shunsuke S. Bronchial Asthma Up-To-Date: Repair and Remodeling of Bronchial Mucosa. Jap J Natl Med Services 1999; 53: 239-245.
6. th ed. Saunders/Elsevier 1999.
7. Kraneveld AD, Hanneke PM, Mirjam K, et al. Key Role for Mast Cells in Nonatopic Asthma. J Immunol 2002; 169: 2044-2053.
8. nd ed. Blackwell Publishing 2000.
9. Bai, TR. Beta-2 adrenergic receptors in asthma: A current perspective. Lung 1992; 170: 125-141.
10. Yang WH, Martinot JB, Pohunek P, et al. Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study. Ann Allergy Asthma Immunol 2007; 99: 555-561.
11. LaForce C, Alexander M, Deckelmann R, et al. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. Allergy 2008; 63: 103-111.
12. Beeh KM, Derom E, Kanniess F, et al. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 2007: 29: 871-878.
13. Sugihara N, Kanada S, Haida M, et al. 24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterol. Respir Med 2010; 104: 1629-1637.
14. Kanniess F, Boulet LP, Pierzhala W, et al. Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study. J Asthma 2008; 45: 887-92.
15. Pearlman DS, Greos L, LaForce C, et al. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist in patients with persistent asthma. Ann Allergy Asthma Immunol 2008; 101: 90-95.
16. Kottakis I, Nandeuil A, Raptis H, et al. Efficacy of the novel very long-acting beta-2 agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patients with persistent asthma. Eur Respir J Suppl 2006. Poster 3858.
17. Dahl R. Ciclesonide for the treatment of asthma. Ther Clin Risk Manag 2006; 2: 25-38.
18. Adachi M, Ishihara K, Inoue H, et al. Efficacy and safety of once-daily inhaled ciclesonide in adults with mild to moderate asthma: a double-blind, placebo-controlled study. Respirology 2007; 12: 566-572.
19. Szefler S, Shashank R, James W, et al. Ciclesonide, A novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005; 128: 1104-1114.
20. Ukena D, Biberger C, Steinijans V, et al. Ciclesonide is more effective than budesonide in the treatment of persistent asthma. Pulm Pharmacol & Ther 2007; 20: 562-570.
21. Boulet LP, Bateman ED, Voves R, et al. A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respir Med 2007; 101: 1677-1686.
22. Buhl R, Vinkler I, Magyar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol & Ther J 2006; 19: 404-412.
23. Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus other inhaled steroids for chronic asthma in children and adults. Cochrane Database Syst Rev 2008; 2.
24. Gauvreau GM, Boulet LP, Postma DS, et al. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clinl Immunol 2005; 116: 285-291.
25. Heijink I, Kauffman H, Vellenga E, et al. Effect of Ciclesonide Treatment on Allergen-Induced Changes in T Cell Regulation in Asthma. Intl Arch Allergy Immunol 2008; 145: 111-121.
26. Ducharme FM, NiChroinin M, Greenstone I, et al. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010; 5:CD005535.
27. Sears MR. The addition of long-acting beta-agonists to inhaled corticosteroids in asthma. Curr Opin Pulm Med 2011; 17: 23-28.
28. Bodzenta-Lukaszk A, Pulka G, Dymek A, et al. Efficacy and safety of fluticssone and formoterol in a single pressurized metered dose inhaler. Respir Med 2011; 105: 674-682.
29. Bodzenta-Lukaszk A, Dymek A, McAulay K, et al. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med 2011; 11: 28.
30. Scichilone N, Battaglia S, Sorino C, et al. Effects of extra-fine beclomethasone/formoterol on both large and small airways in asthma. Allergy 2010; 65: 897-902.
31. Papi A, Paggiaro P, Nicolini G, et al. Beclomethasone/formoterol vs. fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy 2007; 62: 1182-1188.
32. Papi A, Paggiaro PL, Nicolilni G, et al. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 2007; 29: 682-689.
33. Giembycz MA, Newton R. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. Handbook Exp Pharmacol 2011; 204: 415-446.
34. Louw C, Williams Z, Venter L, et al. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge. Respiration 2007; 74: 411-417.
35. Van Schalkwyk E, Strydom K, Williams Z, et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005; 116: 292-298.
36. Bateman ED, Izquierdo JL, Harnest U, et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 2006; 96: 679-686.
37. Bousquet J, Aubier M, Sastre J, et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 2006; 61: 72-78.
38. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176: 1062-1071.
39. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. New Eng J Med 2009; 360: 973-984.
40. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. New Eng J Med 2009; 360: 985-993.
41. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003; 167: 1655-1659.
42. Castro M, Mathur S, Hargreave F, et al. Ann Allergy Asthma Immunol 2010; 105: A43 (Abstract P64)].
43. Busse WW, Katial R, Gossage D, et al. Safety profile, pharmocokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. JACI 2010; 125: 1237-1244.e2
44. O'Byrne P, Boulet LP, Gauvreau G, et al. A single dose of Medi-528, a monoclonal antibody against interleukin-9, is well tolerated in mild and moderate asthmatics in the phase II trial. CHEST: Chest Meeting Abstracts 2007; 132: 478.
45. White B, Leon F, White W, et al. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. Clin Ther 2009; 31: 728-740.
46. Parker JM, Oh CK, LaForce C, et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med 2011; 11: 14.
47. Kim J, Remick DG. Tumor necrosis factor inhibitors for the treatment of asthma. Curr Allergy Asthma Reports 2007; 7: 151-156.
48. Morjaria JB, Chauhan AJ, Babu KS, et al. The role of a soluble TNF-a receptor fusion protein (Etanercept) in corticosteroid refractory asthma: a double blind, randomized placebo-controlled trial. Thorax 2008; 63: 584-591.
49. Holgate ST, Noonan M, Chanez P, et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomized, controlled trial. Eur Respir J 2011; 37: 1352-1359.
50. Mohan AK, Cote TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clinl Infectious Disease 2004; 39: 295-299.
51. Manadan, AM, Joyce K, Sequeira W, et al. Etanercept therapy in patients with a positive tuberculin skin test. Clin Exp Rheumatol 2007; 25: 743-745.
52. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. New Eng J Med 2000; 343: 1054-1063.